Menjugate

N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19, the active ingredient in Menjugate, is a vaccine presented as an injectable solution for intramuscular use. It induces immunity to prevent invasive disease caused by Neisseria meningitidis serogroup C, primarily in children, adolescents and at‑risk adults.

GNH USA supplies Menjugate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards.

Menjugate is a conjugate vaccine that targets Neisseria meningitidis serogroup C and is used to prevent invasive meningococcal disease. - Infants and toddlers: induces protective antibodies to prevent serogroup C meningococcal disease in early childhood. - Adolescents and young adults: boosts immunity to maintain protection during high‑risk age periods. - Adults at increased risk (e.g., complement deficiency, travel to endemic areas): provides targeted protection against serogroup C infection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache or fatigue: mild systemic symptoms.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder with progressive weakness. - Seizures: infrequent occurrence, especially in febrile children. - Severe hypotension: marked drop in blood pressure post‑vaccination. - Acute allergic reaction: including angioedema or bronchospasm.

Before administration, consider the following precautions: - Allergy assessment: avoid in individuals with severe hypersensitivity to any vaccine component. - Pregnancy: use only if the potential benefits outweigh uncertain risks; data are limited. - Immunocompromised patients: vaccine may be less effective; evaluate need on a case‑by‑case basis. - Concurrent vaccines: may be given at separate sites; monitor for additive reactogenicity. - Age restrictions: not approved for use in children under two months of age. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination may be influenced by other agents. Major Interactions (Avoid): - Live bacterial or viral vaccines: concurrent administration may interfere with immune response. - Immunoglobulin or blood products within 4 weeks: can diminish antibody formation. - Therapeutic monoclonal antibodies targeting B cells: may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Corticosteroids or other immunosuppressants: may lower immunogenicity; consider timing of doses. - Prophylactic antipyretics: could blunt antibody response, use only if needed for symptom control. - Co‑administration with other conjugate vaccines: monitor for additive reactogenicity.